Belyea to step down as Metabolic CEO

By Renate Krelle
Thursday, 13 January, 2005

Obesity drug-developer Metabolic (ASX:MBP) announced today that the company is searching for a new CEO and that when an appointment is made, founding CEO Chris Belyea will move into a "scientific and technical" role within the company.

The company said Belyea had expressed his desire to relinquish the CEO role in August 2004. Board chairman Arthur Emmett has since been undertaking the search for a new CEO.

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...

Content from other channels on our network

Indigenous food culture and responsible seafood celebrated

Shaking up whey protein manufacturing technique

Danone to acquire Made Group

Five trends tracked for NZ's fresh produce sector

Poultry and egg producers in lockdown as avian flu detected in WA

FIFA World Cup to generate 156 tonnes of plastic waste

Collaboration provides NZ's largest smart water meter upgrade

Partnership to develop lower-emission titanium production

Refinery transforms CO2 into useable raw materials

Siemens expands Fusesaver manufacturing facility

The Data-Ready Foundation for an AI-Powered Healthcare Future

Innovating chemical dosing & dilution in aged care

A shift in clinical practice: optimal antibiotics for golden staph bloodstream infections

The rise of non-clinical, community-led safe spaces: how lived experience is reshaping suicide prevention

Mandatory VR violence training for nursing students